# Loyal Valley Capital

> Loyal Valley Capital is a VC fund backing Biotechnology and Health Care. See 107 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Shanghai, China
- Total investments: 107
- Last investment: Jul 2026
- Lead investor: 45%
- Fund size: $465M
- Last fund: Dec 2019
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/loyalvalleycapital/
- Website: https://www.loyalvalleycapital.com

Loyal Valley Capital is a thematic, research-driven private equity firm.

## Contacts

5 contacts available for Loyal Valley Capital. Shizune tracks 8 team members at Loyal Valley Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/loyal-valley-capital?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $2.7M–$279M |
| Series B | $25M–$148M |
| Series C | $29M–$300M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 28 | 26% |
| Health Care | 20 | 19% |
| Pharmaceutical | 13 | 12% |
| Medical | 8 | 7% |
| Manufacturing | 8 | 7% |

75 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 20 | 19% |
| Series A | 19 | 18% |
| Series B | 19 | 18% |
| Private Equity | 13 | 12% |
| Funding Round | 12 | 11% |

10 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 66 | 62% |
| United States | 4 | 4% |
| Hong Kong | 1 | 1% |
| The Netherlands | 1 | 1% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Jay Gu | Managing Director | 0 | https://shizune.co/investors/profile/jay-gu-4175 |
| Roy Xie | Managing Director and Head of Healthcare Investments | 5 | https://shizune.co/investors/profile/roy-xie |
| Andy Lin | Founding Partner | 3 | https://shizune.co/investors/profile/andy-lin-2432 |
| Chengbin Li | Partner | 0 | https://shizune.co/investors/profile/chengbin-li |
| Jason Zhao | Managing Director | 0 | https://shizune.co/investors/profile/jason-zhao-7dc0 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| China Immunotech | China Immunotech is a small molecule innovative drug R&D company developing immune cell therapy technologies and products. Including CAR-T and TCR-T cell therapy with independent intellectual property rights. It was founded in March 2018 by famous immunologists. | $29.4M | Series C | Jul 06, 2026 |  |
| DeepSeek | DeepSeek is an artificial intelligence software company that focuses on developing open-source large language models (LLMs). The company researches and develops AI models, machine learning, natural language processing (NLP), and other advanced AI applications. DeepSeek offers an AI assistant app powered by its latest DeepSeek-V3 model. The companyhas released DeepSeek-R1, an open-source model that rivals OpenAI's offerings, which can be freely distilled and commercialized under the MIT license. | $7.4B | Series A | Jun 16, 2026 |  |
| YolTech Therapeutics | Yaotang (Shanghai) Biotechnology is a high-tech biotechnology company focusing on developing a new generation of mRNA drugs and gene editing drugs by combining mRNA in vivo delivery technology and gene editing technology. Through the continuous development and optimization of CRISPR, base editing and other new-generation gene editing tools, andinnovative improvements to the next-generation mRNA production platform and lipid nanocarrier assembly process, Yaotang Bio is committed to developing treatments for genetic diseases and cardiovascular disease. | $73.8M | Series C | May 29, 2026 |  |
| Microtide Biotechnology | Microtide Biotechnology is an innovative company specializing in the field of in vivo cell therapy. The company is dedicated to advancing next-generation biomedical technologies that harness the body’s own cellular mechanisms for disease treatment, focusing on developing safe, effective, and precise therapeutic solutions to improve patient outcomesand redefine the future of regenerative medicine. | $7.3M | Series A | Apr 29, 2026 |  |
| Galaxea AI | Xinghaitu is an intelligent robot technology company that specializes in the development of humanoid robots with embodied intelligence. | $144.7M | Series B | Feb 11, 2026 |  |
| PulseCare | PulseCare is a medtech company that specializes in innovative medical devices and solutions for cardiac and pan-vascular treatment. | $14M | Series A | Nov 06, 2025 |  |
| GRIT Biotechnology | GRIT Biotechnology develops tumor infiltration lymphocytes immunotherapy for solid tumors. The company was founded in 2019 and is headquartered in Shanghai, China. | $84M | Series C | Oct 14, 2025 |  |
| Core Medical Technology | Core Medical Technology is a technology enterprise mainly engaged in the research, production, development, and sales of implantable left ventricular assist devices, extracorporeal ventricular assist devices, percutaneous interventional ventricular assist devices, and equipment. The company was founded in 2016 and is based in Shenzhen, China. | $100M | Series D | Apr 24, 2025 |  |
| Sinovent | Founded in 2016, Sinovent is a global biopharmaceutical company focused on innovation. Sinovent is centered around global standard excellence through its advanced biotechnology platform, decades of management experience, as well as financial support. Sinovent uniquely combines its expertise in science, management and finance, to develop and promoteadvanced treatment methods to solve worldwide healthcare problems. Currently, the company has 12 products in development, primarily in oncology, auto-immune diseases, and infectious diseases. | $97.3M | Series E | Feb 20, 2024 |  |
| DP Technology | Deep Technology uses a new generation of molecular simulation technology to tackle micro-scale industrial design difficulties. Founded in 2018 and is based in Beijing China. | $99.2M |  | Aug 18, 2023 |  |

10 of 107 investments shown.

## Co-investors
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund, 12 deals together
- [Lilly Asia Ventures](https://shizune.co/investors/profile/lilly-asia-ventures) — VC Fund, 10 deals together
- [Tencent](https://shizune.co/investors/profile/tencent) — VC Fund, 9 deals together
- [IDG Capital](https://shizune.co/investors/profile/idg-capital-partners) — VC Fund, 7 deals together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 7 deals together
- [Zhengxingu Capital](https://shizune.co/investors/profile/zhengxingu-capital) — VC Fund, 7 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

### Similar country
- [IDG Capital](https://shizune.co/investors/profile/idg-capital-partners) — VC Fund
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund
- [HSG](https://shizune.co/investors/profile/sequoia-capital-china) — VC Fund

## Featured in investor lists
- [Life Science Investors in Asia](https://shizune.co/investors/life-science-investors-asia)
- [Life Science Investors in China](https://shizune.co/investors/life-science-investors-china)
- [Life Science VC Funds in Asia](https://shizune.co/investors/life-science-vc-funds-asia)
- [Life Science VC Funds in China](https://shizune.co/investors/life-science-vc-funds-china)
- [Restaurants VC Funds in China](https://shizune.co/investors/restaurants-vc-funds-china)
- [Hospitality Investors in China](https://shizune.co/investors/hospitality-investors-china)

## FAQ

### What does Loyal Valley Capital invest in?

Loyal Valley Capital invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Series C and Series A stage. Most of the 107 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Loyal Valley Capital's check size?

Loyal Valley Capital typically joins rounds of $2.7M–$279M at Series A, $25M–$148M at Series B and $29M–$300M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Loyal Valley Capital participates in.

### How do I contact Loyal Valley Capital?

Public channels for Loyal Valley Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Loyal Valley Capital?

The team at Loyal Valley Capital includes Jay Gu (Managing Director), Roy Xie (Managing Director and Head of Healthcare Investments) and Andy Lin (Founding Partner), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co